BenevolentAI SA

BenevolentAI S.A. is a clinical-stage company focused on drug discovery and development, powered by artificial intelligence. Its unique BenevolentAI platform supports an extensive internal pipeline of pharmaceutical programs. The company addresses a broad array of therapeutic areas, including atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral conditions, oncology, Parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. Through a collaboration with AstraZeneca, BenevolentAI aims to deepen understanding of complex disease biology and identify novel targets. Founded in 2013, the enterprise is headquartered in London, United Kingdom.